TANDEM DIABETES CARE INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($83.4m) ($73.0m) ($122.6m) ($24.8m) ($34.4m) $15.6m ($94.6m) ($222.6m) ($96.0m) ($204.7m)
Net Income (Loss) Available to Common Stockholders, Basic $15.6m ($94.6m) ($222.6m)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($122.6m) ($24.8m) ($34.4m) $15.6m ($94.6m) ($222.6m) ($96.0m) ($204.7m)
Depreciation, Depletion and Amortization $5.5m $6.9m $5.8m $6.1m $10.5m $13.8m $14.3m $15.7m $16.6m $17.7m
Amortization of Debt Issuance Costs $1.7m $1.9m $2.2m $2.1m $1.9m
Amortization of Debt Issuance Costs and Discounts $274k $1.9m $1.7m $0 $10.1m $1.7m $1.9m $2.2m $2.1m $1.9m
Amortization of Intangible Assets $300k $300k $300k $300k $1.2m $2.2m $2.0m $1.9m $1.9m $2.5m
Deferred Income Tax Expense (Benefit) ($25k) ($2.1m) $0 $0 $0 $0 $0
Share-based Payment Arrangement, Noncash Expense $11.7m $12.6m $23.7m $58.1m $58.4m $60.8m $84.9m $88.1m $101.4m $92.4m
Share-based Payment Arrangement, Expense $11.7m $12.6m $23.7m $58.1m $58.4m $60.8m $84.9m $88.1m $101.4m $92.4m
Equity Method Investment, Other than Temporary Impairment $2.0m
Impairment of Intangible Assets, Finite-lived $0
Gain (Loss) on Extinguishment of Debt $0 ($5.3m) $0 $0 $0 $0 ($1.3m) $0
Income (Loss) from Equity Method Investments $0 $0 ($2.1m) ($14.2m)
Income Tax Expense (Benefit) ($15k) $8k $51k $149k ($1.9m) $335k $1.7m $2.4m $4.2m $4.4m
Interest Expense Nonoperating $7.4m $7.9m
Other Nonoperating Income (Expense) ($5.4m) ($10.1m) ($77.9m) ($7.9m) ($28.3m) ($6.8m) ($4k) $13.0m $7.3m ($13.0m)
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable ($2.3m) $10.4m $15.8m $13.7m $38.8m $31.0m $7.8m ($4.3m) $20.8m $56.8m
Increase (Decrease) in Inventories $6.9m $5.9m ($6.8m) $31.0m $15.4m $5.0m $42.5m $46.1m ($5.8m) ($24.8m)
Increase (Decrease) in Accounts Payable $3.2m ($2.0m) $1.6m $8.9m $1.1m $10.3m $24.5m ($4.9m) ($2.4m) $2.2m
Inventory Write-down $3.3m $26k $607k $2.4m ($57k) $467k
Operating Expenses $101.6m $107.0m $134.5m $210.9m $268.5m $353.6m $505.8m $600.9m $588.7m $733.3m
Net Cash Provided by (Used in) Operating Activities ($61.2m) ($66.1m) ($8.3m) $41.9m $24.7m $111.4m $50.5m ($31.8m) $24.2m ($9.7m)
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $8.9m $5.7m $3.0m $19.5m $27.4m $14.2m $34.1m $26.8m $19.2m $19.9m
Net Cash Provided by (Used in) Investing Activities $10.4m $2.8m ($90.7m) ($57.0m) ($296.1m) ($186.9m) $33.2m ($85.7m) ($23.5m) $72.9m
Cash flows from financing activities:
Proceeds from Issuance of Common Stock $2.3m $570k $2.4m $23.9m $66.9m $51.3m $17.5m $4.2m ($6.7m) $2.6m
Payments for Repurchase of Common Stock $0 $0 $30.0m $0
Proceeds from (Payments for) Other Financing Activities ($675k) ($71k) $183k $0
Net Cash Provided by (Used in) Financing Activities $52.3m $32.4m $117.2m $24.2m $314.4m $51.9m $16.9m $4.1m $8.4m ($43.4m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $0 $0 $191k $387k $153k $827k ($212k) $1.3m $1.6m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $0 $18.1m $9.3m $43.4m ($23.4m) $101.3m ($113.6m) $10.4m $21.4m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $51.2m $94.6m $71.2m $172.5m $58.9m $69.2m $90.6m
Cash, Cash Equivalents, and Short-term Investments $53.5m $129.0m $176.5m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $4.4m $7.9m $10.8m $0 $2.7m $4.3m $4.3m $7.6m $3.1m $5.0m
Income Taxes Paid, Net $23k $22k $16k $67k $177k $260k $411k $1.9m $3.1m $5.1m

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.